Vontobel Holding’s Arcus Biosciences RCUS Stock Holding History

Vontobel Holding’s Portfolio RCUS Stock Details RCUS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-10,000	Closed	-$349K	–	1186
2021 Q3	$349K	Hold	10,000	–	–	﹤0.01%	903
2021 Q2	$273K	Hold	10,000	–	–	﹤0.01%	949
2021 Q1	$281K	Hold	10,000	–	–	﹤0.01%	830
2020 Q4	$414K	Buy	+10,000	New	+$242K	﹤0.01%	704

Other funds holding RCUS

EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

PHS

PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Alphabet Inc Mountain View, California $4.02B AUM 215.74% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

OCA

Octagon Capital Advisors New York $904M AUM 737.04% 1-Year Est. Return

Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return

Vontobel Holding's RCUS Position: Q4 2021 in Review

Vontobel Holding sold out of Arcus Biosciences (RCUS) in Q4 2021, closing a stake of 10,000 shares — an estimated $349K sold.

Vontobel Holding first reported a position in RCUS in Q4 2020 and held it in 4 quarters. The position peaked at $414K in Q4 2020. 142 funds tracked by Wall St. Rank hold RCUS as of Q4 2021.

Vontobel Holding reported no remaining Arcus Biosciences position as of Q4 2021 after selling out during the quarter.
Vontobel Holding sold 10,000 Arcus Biosciences shares in Q4 2021, an estimated $349K.
Vontobel Holding first reported a position in Arcus Biosciences in Q4 2020 and held it in 4 quarters.
Vontobel Holding's Arcus Biosciences position peaked at $414K in Q4 2020.
142 funds tracked by Wall St. Rank held Arcus Biosciences as of Q4 2021.

Based on Vontobel Holding's 13F filing for Q4 2021, filed 10 Feb 2022.